Assessment of left ventricular systolic and diastolic function with conventional and tissue Doppler echocardiography imaging techniques in patients administered tyrosine kinase inhibitor

Turk Kardiyoloji Dernegi Arsivi

Volumn 40, Issue 7, 2012, Pages 595-605

  Alihanoǧlu, Yusuf Izzettin ^a   Kaya, Zeynettin ^b   Ari, Hatem ^c   Karaarslan, Şükrü ^d   Yildiz, Bekir Serhat ^a   Karanfil, Mustafa ^e   Yazici, Mehmet ^e   Börüban, Melih Cem ^e   Özdemir, Kurtuluş ^e   Ülgen, Mehmet Siddik ^f  

^a DENIZLI STATE HOSPITAL   (Turkey)

^b Numune State Hospital   (Turkey)

^c Beyhekim State Hospital   (Turkey)

^d Nigde State Hospital   (Turkey)

^e SELCUK UNIVERSITY   (Turkey)

^f DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Cardiotoxicity; Drug interactions; Echocardiography, Doppler; Elasticity imaging techniques; Heart failure chemically induced; Neoplasms drug therapy; Protein tyrosine kinases antagonists inhibitors; Ventricular function, left

Indexed keywords

ERLOTINIB; IMATINIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; DIASTOLIC DYSFUNCTION; DRUG EFFECT; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART PERFORMANCE; HEART STROKE VOLUME; HUMAN; INTERMETHOD COMPARISON; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MALE; MYOCARDIAL PERFORMANCE INDEX; OUTCOME ASSESSMENT; SCORING SYSTEM; SYSTOLE; TISSUE DOPPLER IMAGING; ANTAGONISTS AND INHIBITORS; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECTS; MIDDLE AGED; NEOPLASMS; PHYSIOLOGY; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DIASTOLE; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER, PULSED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SYSTOLE; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84882962569     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: 10.5543/tkda.2012.53896     Document Type: Article

References (27)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
2. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470-81.
3. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
4. Chen MH, Kerkelä R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008;118:84-95.
5. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-70.
6. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-9. (Pubitemid 46621999)
7. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006;24:1329-31. (Pubitemid 46621994)
8. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003;108:1146-62. (Pubitemid 37074844)
9. Maitland ML. Cardiovascular toxicity of new agents. Clin Adv Hematol Oncol 2008;6:657-9.
10. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-9. (Pubitemid 350236338)
11. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16. (Pubitemid 44175142)
12. Midgley RS, Kerr DJ, Flaherty KT, Stevenson JP, Pratap SE, Koch KM, et al. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 2007;18:2025-9. (Pubitemid 350286244)
13. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008;112:2500-8.
14. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008;19:1613-8.
15. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. (Pubitemid 46089672)
16. Wang M, Yip GW, Wang AY, Zhang Y, Ho PY, Tse MK, et al. Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. J Am Coll Cardiol 2003;41:820-6. (Pubitemid 36308391)
17. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000;102:1788-94.
18. Rodriguez L, Garcia M, Ares M, Griffin BP, Nakatani S, Thomas JD. Assessment of mitral annular dynamics during diastole by Doppler tissue imaging: comparison with mitral Doppler inflow in subjects without heart disease and in patients with left ventricular hypertrophy. Am Heart J 1996;131:982-7. (Pubitemid 26135764)
19. Alam M, Wardell J, Andersson E, Samad BA, Nordlander R. Effects of first myocardial infarction on left ventricular systolic and diastolic function with the use of mitral annular velocity determined by pulsed wave doppler tissue imaging. J Am Soc Echocardiogr 2000;13:343-52. (Pubitemid 30322432)
20. Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006;7:141-6. (Pubitemid 43257199)
21. Tei C, Nishimura RA, Seward JB, Tajik AJ. Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr 1997;10:169-78. (Pubitemid 127789844)
22. Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB. Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 1998;82:1071-6. (Pubitemid 28507090)
23. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998;81:1157-61. (Pubitemid 28232689)
24. Schaefer A, Meyer GP, Hilfiker-Kleiner D, Brand B, Drexler H, Klein G. Evaluation of Tissue Doppler Tei index for global left ventricular function in mice after myocardial infarction: comparison with Pulsed Doppler Tei index. Eur J Echocardiogr 2005;6:367-75. (Pubitemid 41258930)
25. Gaibazzi N, Petrucci N, Ziacchi V. Left ventricle myocardial performance index derived either by conventional method or mitral annulus tissue-Doppler: a comparison study in healthy subjects and subjects with heart failure. J Am Soc Echocardiogr 2005;18:1270-6. (Pubitemid 41821170)
26. Eidem BW, Sapp BG, Suarez CR, Cetta F. Usefulness of the myocardial performance index for early detection of an-thracycline-induced cardiotoxicity in children. Am J Cardiol 2001;87:1120-2, A9.
27. Senju N, Ikeda S, Koga S, Miyahara Y, Tsukasaki K, Tomonaga M, et al. The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies. Heart Vessels 2007;22:393-7. (Pubitemid 350201435)